HMGB1 as a potential biomarker and therapeutic target for severe COVID-19.
COVID-19
Cell culture
Cell death
HMGB1
Immunology
Infectious disease
Inflammation
Microbiology
Virology
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
01
07
2020
revised:
26
08
2020
accepted:
03
12
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
Statut:
epublish
Résumé
COVID-19 has attracted global attention due to its rapid spread around the world with substantial morbidity and associated mortality. Severe COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis and septic shock leading to death. These complications are thought to result from an overactivation of the immune system, leading to a cytokine storm syndrome associated with multiple organ failure. Here, we report that high mobility group box 1 (HMGB1), a prototypical damage-associated molecular pattern (DAMP) and a central mediator of lethal inflammation, could be a potential target for innovative therapeutic strategies for COVID-19. Serum HMGB1 in severe COVID-19 patients is elevated (189.40 ± 140.88 ng/ml). Exogenous HMGB1 induces the expression of SARS-CoV-2 entry receptor ACE2 in alveolar epithelial cells in an AGER-dependent manner. Importantly, genetic (using AGER siRNA) or pharmacological (using glycyrrhizin, chloroquine, hydroxychloroquine, and FPS-ZM1) inhibition of the HMGB1-AGER pathway blocks ACE2 expression. Thus, HMGB1 inhibitors are likewise promising drug candidates for the treatment of patients suffering from COVID-19.
Identifiants
pubmed: 33313438
doi: 10.1016/j.heliyon.2020.e05672
pii: S2405-8440(20)32515-9
pmc: PMC7720697
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e05672Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 1999 Jul 9;285(5425):248-51
pubmed: 10398600
Lancet. 2020 Mar 28;395(10229):1015-1018
pubmed: 32197103
Autophagy. 2020 Dec;16(12):2273-2275
pubmed: 32713288
Autophagy. 2020 Mar 18;:1-13
pubmed: 32186434
Front Immunol. 2020 Jun 26;11:1580
pubmed: 32670297
Comb Chem High Throughput Screen. 2020 Jul 27;:
pubmed: 32723229
Mol Aspects Med. 2014 Dec;40:1-116
pubmed: 25010388
Nat Med. 2020 Jun;26(6):808-809
pubmed: 32488217
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Mediators Inflamm. 2020 Jul 16;2020:7527953
pubmed: 32724296
Pharmacol Ther. 2020 Oct;214:107618
pubmed: 32592716
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Mol Med. 2020 May 7;26(1):42
pubmed: 32380958
Horm Res Paediatr. 2020;93(2):73-75
pubmed: 32375153
Nature. 1979 Oct 25;281(5733):689-90
pubmed: 233133
Annu Rev Med. 2018 Jan 29;69:349-364
pubmed: 29106804
Biomed Res Int. 2017;2017:9719647
pubmed: 28484719
Biochem Pharmacol. 2013 Aug 1;86(3):410-8
pubmed: 23707973
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Paediatr Respir Rev. 2017 Jun;23:40-49
pubmed: 28416135
J Clin Invest. 2012 Apr;122(4):1377-92
pubmed: 22406537
Expert Opin Ther Targets. 2014 Mar;18(3):257-68
pubmed: 24392842
J Cell Biol. 2010 Sep 6;190(5):881-92
pubmed: 20819940
Lancet. 2003 Jun 14;361(9374):2045-6
pubmed: 12814717
Autophagy. 2020 Nov;16(11):2069-2083
pubmed: 31920150
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Immunol Rev. 2012 Sep;249(1):158-75
pubmed: 22889221
J Exp Med. 2007 Nov 26;204(12):2913-23
pubmed: 17984303
J Leukoc Biol. 2007 Jan;81(1):1-5
pubmed: 17032697
Chem Biol. 2007 Apr;14(4):431-41
pubmed: 17462578
PLoS Pathog. 2020 May 22;16(5):e1008536
pubmed: 32442210